Skip to main content

What the FDA labels say about taking them together

Lomitapide and lovastatin

Lomitapide's FDA label of March 30, 2026 names lovastatin in its drug interactions section; the lovastatin label PlainMeds reads does not name lomitapide. The lomitapide label: “Simvastatin and lovastatin exposure increase with JUXTAPID.”

Check it at the source: the lomitapide FDA label on DailyMed (effective March 30, 2026, Chiesi USA, Inc.); the lovastatin FDA label on DailyMed (effective May 6, 2026, Lupin Pharmaceuticals, Inc.).

What does the lomitapide label say about lovastatin?

Lomitapide label, drug interactions

Simvastatin and lovastatin exposure increase with JUXTAPID.

Lomitapide label, warnings and precautions

Myopathy with Concomitant Use of Simvastatin or Lovastatin The risk of myopathy, including rhabdomyolysis, with simvastatin and lovastatin monotherapy is dose related.

Source: FDA drug label (Juxtapid), Chiesi USA, Inc., effective March 30, 2026 (SPL set 61a0be9d-ee58-43e0-b5cb-141011835081), via openFDA; the full label on DailyMed

What does the lovastatin label say about lomitapide?

Lovastatin's label (effective May 6, 2026) does not name lomitapide in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Lovastatin), Lupin Pharmaceuticals, Inc., effective May 6, 2026 (SPL set df7ddf4f-d569-431e-81f1-9129d7043150), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Lomitapide generic labelers
19Lovastatin generic labelers
LomitapideLovastatin
Labeled forHigh cholesterolHigh cholesterol, Heart attack and coronary artery disease
Boxed warningYesNo
Pharmacy cost (NADAC)n/a$0.0436 per tablet 20 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?